Cardiovascular drugs do not affect COVID-19 outcomes—such as disease severity, hospitalizations, or deaths—according to an analysis of all relevant studies published as of November 2020. The findings are published in the British Journal of Clinical Pharmacology.
Investigators included 429 studies in a qualitative analysis and 390 in a quantitative analysis.
The results indicate that patients at risk of or with confirmed COVID-19 should continue taking cardiovascular drugs as prescribed.
“This is the most comprehensive analysis of the extensive amount of data published in this area,” said senior author Munir Pirmohamed, MBChB, PhD, of the University of Liverpool, in the UK. “Given that we are still in the midst of a pandemic, the evidence base will continue to build, and we will therefore update our analysis.”
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14927
About Journal
Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.
About Wiley
Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world’s knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at Wiley.com, like us on Facebook and follow us on Twitter and LinkedIn.